Description
Anaferon Pharmacodynamics
During preventive and therapeutic use the drug has immunomodulatory and antiviral action. Efficacy against influenza viruses, parainfluenza, herpes simplex viruses of types 1 and 2 (labial herpes, genital herpes), other herpes viruses (chickenpox, infectious mononucleosis), enteroviruses, tick-borne encephalitis virus, rotavirus, coronavirus, calicivirus, adenovirus, respiratory syncytial virus (PC virus) is established experimentally and clinically. The drug decreases the virus concentration in the affected tissues, affects the system of endogenous interferons and associated cytokines, induces formation of endogenous “early” interferons (IFN a/?) and gamma interferon (IFN ?).
Stimulates humoral and cellular immune response. It increases the production of antibodies (including secretory IgA), activates the functions of T-actors, T-helpers (Tx), and normalizes their ratio. Increases the functional reserve of Tx and other cells involved in the immune response. It is an inducer of mixed Txl and Tx2-type immune response: it increases the production of Txl cytokines (IFN ?, IL-2) and Tx2 (IL-4, 10), normalizes (modulates) the balance of Tx1/Tx2 activities. Increases the functional activity of phagocytes and natural killer cells (EC cells). It has antimutagenic properties.
Indications
Prevention and treatment of acute respiratory viral infections (including influenza).
Complex therapy of infections caused by herpes viruses (infectious mononucleosis, varicella, labial herpes, genital herpes).
Complex therapy and prevention of relapses of chronic herpesvirus infection, including labial and genital herpes.
Complex therapy and prevention of other acute and chronic viral infections caused by tick-borne encephalitis virus, enterovirus, rotavirus, coronavirus, kalitsivirus.
Use as part of the complex therapy of bacterial infections
Complex therapy of secondary immunodeficiency disorders of various etiologies, including the prevention and treatment of complications of viral and bacterial infections.
Contraindications
Increased individual sensitivity to the drug components. Anaferon for children and persons under 18 years old is indicated.
Pregnancy and lactation
The safety of Anaferon administration during pregnancy and lactation has not been studied. It is necessary to take into consideration the risk/benefit ratio if it is necessary to use this medicine.
Dosage and administration method
- Orally, not with meals. The tablet should be kept in the mouth until dissolved.
SARS, influenza, intestinal infections, herpesvirus infections, neuroinfections.
On the 1st day of treatment take 8 tablets under the following scheme: 1 tablet every 30 minutes during the first 2 hours (a total of 5 tablets in 2 hours), then during the same day take another 1 tablet 3 times at regular intervals. On the 2nd day and further take 1 tablet 3 times a day until full recovery. - If there is no improvement on the third day of treatment with the drug of acute respiratory viral infections and influenza should consult a doctor.
During the epidemic season, for prophylactic purposes, the drug is taken daily once a day for 1-3 months. - Genital herpes. In acute manifestations of genital herpes, the drug is taken at regular intervals according to the following scheme: Day 1-3 – 1 tablet 8 times a day, then 1 tablet 4 times a day – at least 3 weeks.
- For prevention of relapses of chronic herpesvirus infection – 1 tablet a day. The recommended duration of the prophylactic course is determined individually and can be up to 6 months.
- When using the drug for the treatment and prevention of immunodeficiency states, in the complex therapy of bacterial infections – take 1 tablet a day.
If necessary, the drug can be combined with other antiviral and symptomatic agents.
